Dyadic International, Inc. (DYAI): Price and Financial Metrics


Dyadic International, Inc. (DYAI): $2.25

-0.01 (-0.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DYAI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

DYAI POWR Grades


  • Sentiment is the dimension where DYAI ranks best; there it ranks ahead of 84.48% of US stocks.
  • The strongest trend for DYAI is in Stability, which has been heading up over the past 124 days.
  • DYAI ranks lowest in Quality; there it ranks in the 3rd percentile.

DYAI Stock Summary

  • For DYAI, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
  • DYAI's price/sales ratio is 38.26; that's higher than the P/S ratio of 95.41% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.1 for Dyadic International Inc; that's greater than it is for only 8.17% of US stocks.
  • Stocks that are quantitatively similar to DYAI, based on their financial statements, market capitalization, and price volatility, are TTNP, UTHR, PSNL, PXLW, and KOPN.
  • Visit DYAI's SEC page to see the company's official filings. To visit the company's web site, go to www.dyadic.com.

DYAI Valuation Summary

  • In comparison to the median Healthcare stock, DYAI's EV/EBIT ratio is 148.12% lower, now standing at -14.1.
  • DYAI's price/sales ratio has moved up 9 over the prior 29 months.
  • Over the past 29 months, DYAI's EV/EBIT ratio has gone down 0.3.

Below are key valuation metrics over time for DYAI.

Stock Date P/S P/B P/E EV/EBIT
DYAI 2021-08-31 82.2 7.7 -15.3 -14.1
DYAI 2021-08-30 83.8 7.8 -15.6 -14.4
DYAI 2021-08-27 84.4 7.9 -15.7 -14.5
DYAI 2021-08-26 81.9 7.6 -15.2 -14.1
DYAI 2021-08-25 78.0 7.3 -14.5 -13.4
DYAI 2021-08-24 64.5 6.0 -12.0 -10.8

DYAI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DYAI has a Quality Grade of D, ranking ahead of 6.48% of graded US stocks.
  • DYAI's asset turnover comes in at 0.074 -- ranking 281st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows DYAI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.074 0.193 -1.227
2021-03-31 0.056 0.120 -0.849
2020-12-31 0.049 0.110 -0.565
2020-09-30 0.049 0.056 -0.409
2020-06-30 0.048 0.009 -0.292
2020-03-31 0.042 0.115 -0.263

DYAI Price Target

For more insight on analysts targets of DYAI, see our DYAI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.00 Average Broker Recommendation 1.5 (Moderate Buy)

DYAI Stock Price Chart Interactive Chart >

Price chart for DYAI

DYAI Price/Volume Stats

Current price $2.25 52-week high $6.89
Prev. close $2.26 52-week low $1.74
Day low $2.20 Volume 32,329
Day high $2.30 Avg. volume 62,207
50-day MA $2.54 Dividend yield N/A
200-day MA $3.95 Market Cap 63.59M

Dyadic International, Inc. (DYAI) Company Bio


Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd., as well as with the Israel Institute for Biological Research; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; research collaboration with Sanofi-Aventis Deutschland GmbH; research and commercialization collaboration with Serum Institute of India Pvt.; and nonexclusive research collaboration with WuXi Biologics. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.


DYAI Latest News Stream


Event/Time News Detail
Loading, please wait...

DYAI Latest Social Stream


Loading social stream, please wait...

View Full DYAI Social Stream

Latest DYAI News From Around the Web

Below are the latest news stories about Dyadic International Inc that investors may wish to consider to help them evaluate DYAI as an investment opportunity.

DYAI: Don’t Put All Your Eggs in One Basket

By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Since Our Last Update Since our last update , Dyadic International Inc. (NASDAQ:DYAI) announced receipt of the NIIMBL coronavirus grant, early proof-of-concept of C1 producing cannabinoids and an exclusive license agreement with Phibro. Recent highlights: ➢ NIIMBL coronavirus grant - December 2021 ➢ C1 engineered to

Yahoo | February 22, 2022

Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing

Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.

Yahoo | February 15, 2022

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Dyadic International (DYAI) and SCYNEXIS (SCYX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), Dyadic International (DYAI – Research Report) and SCYNEXIS (SCYX – Research Report). Alnylam Pharma (ALNY) In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Hold rating on Alnylam Pharma, with a price target of $154.00. The company's shares closed last Thursday at $150.86. According to TipRanks.

Christine Brown on TipRanks | February 11, 2022

Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine

The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a targeted disease.JUPITER, Fla., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accele

Yahoo | February 10, 2022

Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference

JUPITER, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company’s CEO Mark Emalfarb will be presenting at the upcoming 2022 BIO CEO & I

Yahoo | February 7, 2022

Read More 'DYAI' Stories Here

DYAI Price Returns

1-mo -1.32%
3-mo -39.84%
6-mo -39.26%
1-year -44.85%
3-year -44.85%
5-year 60.71%
YTD -50.22%
2021 -15.99%
2020 3.86%
2019 174.07%
2018 35.97%
2017 -16.27%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6655 seconds.